Business
Vor Licenses Clinical-Stage CD33 CAR-T Therapy
Vor Licenses Clinical-Stage CD33 CAR-T Therapy.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9073E\n PureTech Health PLC\n 11 November 2020\n \n \n \n \n 11 November 2020\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech Founded Entity Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute\n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vor, today announced an exclusive licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for intellectual property related to a clinical-stage anti-CD33 chimeric antigen receptor T-cell (CAR-T) therapy candidate. This CAR-T construct was devised by T-cell expert Dr Terry Fry during his tenure at the Pediatric Oncology Branch of the NCI, where he oversaw development of this therapeutic candidate from bench to bedside; it is currently being evaluated in a multi-site Phase 1/2 clinical trial in children and young adults with relapsed or refractory acute myeloid leukaemia (AML).\n \n \n \n \n \n The full text of the announcement from Vor is as follows:\n \n \n \n \n \n Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute\n \n \n \n \n \n CAMBRIDGE, Mass. - November 11, 2020 - \n \n \n Vor Biopharma\n \n \n , an oncology company pioneering engineered haematopoietic stem cells (eHSCs) for the treatment of cancer, today announced an exclusive licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for intellectual property related to a clinical-stage anti-CD33 chimeric antigen receptor T-cell (CAR-T) therapy candidate. This CAR-T construct was devised by T-cell expert Dr Terry Fry during his tenure at the Pediatric Oncology Branch of the NCI, where he oversaw development of this therapeutic candidate from bench to bedside; it is currently being evaluated in a multi-site Phase 1/2 clinical trial in children and young adults with relapsed or refractory acute myeloid leukaemia (AML).\n \n \n \n \n \n \"As a class, CAR-T cell therapies have had a major positive impact on...